Kim, Helena K.
Voineskos, Aristotle N. http://orcid.org/0000-0003-0156-0395
Neufeld, Nicholas H. http://orcid.org/0000-0002-8046-0212
Alexopoulos, George S. http://orcid.org/0000-0001-5677-7001
Bingham, Kathleen S.
Flint, Alastair J.
Marino, Patricia
Rothschild, Anthony J.
Whyte, Ellen M.
Mulsant, Benoit H. http://orcid.org/0000-0002-0303-6450
Funding for this research was provided by:
Fondation Brain Canada
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
Foundation for the National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Canada Foundation for Innovation
University of Toronto
Patient-Centered Outcomes Research Institute
Ontario Brain Institute
Alzheimer's Association
Allergan
Janssen Biotech
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Takeda Medical Research Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 10 August 2023
Revised: 21 February 2024
Accepted: 7 March 2024
First Online: 19 March 2024
Competing interests
: HKK has no financial relationships with commercial interests. ANV receives funding from the National Institute of Mental Health (NIMH), Canadian Institutes of Health Research, Canada Foundation for Innovation, Centre for Addiction and Mental Health (CAMH) Foundation, and the University of Toronto. NHN receives grant support from the Canadian Institutes of Health Research, Physicians’ Services Incorporated Foundation, and the University of Toronto. GA has served on an advisory board of Otsuka and has been on the speakers bureau of Otsuka. KSB receives grant support from the University of Toronto. AJF has received grant support from the US National Institutes of Health, the Patient-Centered Outcomes Research Institute, the Canadian Institutes of Health Research, Brain Canada, the Ontario Brain Institute, and Alzheimer’s Association. PM has no financial relationships with commercial interests. AJR has received grant or research support from Janssen, Otsuka, and the Irving S. and Betty Brudnick Endowed Chair in Psychiatry; is a consultant to Daiichi Sankyo, Inc, Sage Therapeutics, Xenon Pharmaceuticals, Lupin Pharmaceuticals, Zydus Pharmaceuticals (USA), Inc., and Neumora Therapeutics; and has received royalties for the Rothschild Scale for Antidepressant Tachyphylaxis (RSAT)®, Clinical Manual for the Diagnosis and Treatment of Psychotic Depression, American Psychiatric Press, 2009; The Evidence-Based Guide to Antipsychotic Medications, American Psychiatric Press, 2010; The Evidence-Based Guide to Antidepressant Medications, American Psychiatric Press, 2012, and from UpToDate®. EMW receives grant support from the NIMH and Health Resources and Services Administration. Dr. Mulsant holds and receives support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He currently receives or has received research support from Brain Canada, the CAMH Foundation, the Canadian Institutes of Health Research, and the US National Institutes of Health (NIH); research support from Bristol-Myers Squibb (medications for an NIH-funded clinical trial), Eli-Lilly (medications for an NIH-funded clinical trial), Pfizer (medications for an NIH-funded clinical trial), Capital Solution Design LLC (software used in a study funded by CAMH Foundation), and HAPPYneuron (software used in a study funded by Brain Canada).